Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

NCT02716103 · clinicaltrials.gov ↗
COMPLETED
Status
45
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Boston Medical Center